Targeting of human p53-overexpressing tumor cells by an HLA A*0201- restricted murine T-cell receptor expressed in Jurkat T cells

Cancer Research

Volumn 60, Issue 3, 2000, Pages 693-701

  Liu, Xiping ^a   Peralta, Elizabeth A ^a   Ellenhorn, Joshua D I ^a   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; COMPLEMENTARY DNA; HLA ANTIGEN; PROTEIN P53; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN RECOGNITION; ARTICLE; DRUG POTENCY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST;

ANIMALS; CLONING, MOLECULAR; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033954002     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Finlay, C. A., Hinds, P. W., and Levine, A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57: 1083-1093, 1989.
2. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA, 86: 8763-8767, 1989.
3. Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J., Schaid, D., and Sommer, S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA, 93: 1093-1096, 1996.
4. Zambetti, G. P., and Levine, A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J., 7: 855-865, 1993.
5. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E., and Levine, A. J. p53 as a target for vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge. Proc. Natl. Acad. Sci. USA, 93: 4781-4786, 1996.
6. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De, C. C., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., and DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183: 1357-1365, 1996.
7. Vierboom, M. P., Nijman, H. W., Offringa, R., van der Voort, E. I., van Hall, T., van den Broek B., Fleuren, G. J., Kenemans, P., Kast, W. M., and Melief, C. J. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med., 186: 695-704, 1997.
8. Maehara, Y., Kakeji, Y., Watanabe, A., Baba, H., Kusumoto, H., Kohnoe, S., and Sugimachi, K. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer (Phila.), 85: 302-308, 1999.
9. Maehara, Y., Kakeji, Y., Watanabe, A., Baba, H., Kusumoto, H., Kohnoe, S., and Sugimachi, K. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer (Phila.), 85: 302-308, 1999.
10. Bertholet, S., Iggo, R., and Corradin, G. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur. J. Immunol., 27: 798-801, 1997.
11. McCarty, T. M., Liu, X., Sun, J. Y., Peralta, E. A., Diamond, D. J., and Ellenhorn, J. D. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res., 58: 2601-2605, 1998.
12. Stenholm, A. C., Kirkin, A. F., and Zeuthen, J. In vivo eradication of an established human melanoma by an in vitro generated autologous cytotoxic T cell clone: a SCID mouse model. Int. J. Cancer, 77: 476-480, 1998.
13. Chung, S., Wucherpfennig, K. W., Friedman, S. M., Hafler, D. A., and Strominger, J. L. Functional three-domain single-chain T-cell receptors. Proc. Natl. Acad. Sci. USA, 91: 12654-12658, 1994.
14. Yu, Z., Liu, X., McCarty, T. M., Diamond, D. J., and Ellenhorn, J. D. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J. Surg. Res., 69: 337-343, 1997.
15. Theobald, M., Biggs, J., Dittmer, D., Levine, A., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA, 92: 11993-11997, 1995.
16. Hara, T., Fu, S. M., and Hansen, J. A. Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J. Exp. Med., 161: 1513-1524, 1985.
17. Guinan, E. C., Gribben, J. G., Boussiotis, V. A., Freeman, G. J., and Nadler, L. M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood, 84: 3261-3282, 1994.
18. Nunes, J., Klasen, S., Ragueneau, M., Pavon, C., Couez, D., Mawas, C., Bagnasco, M., and Olive, D. CD28 mAbs with distinct binding properties differ in their ability to induce T cell activation: analysis of early and late activation events. Int. Immunol., 5: 311-315, 1993.
19. Salter, R. D., and Cresswell, P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J., 5: 943-949, 1986.
20. Fogh, J., Fogh, J. M., and Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst., 59: 221-226, 1977.
21. Lieber, M., Mazzetta, J., Nelson-Rees, W., Kaplan, M., and Todaro, G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int. J. Cancer, 15: 741-747, 1975.
22. Chen, W. H., Horoszewicz, J. S., Leong, S. S., Shimano, T., Penetrante, R., Sanders, W. H., Berjian, R., Douglass, H. O., Martin, E. W., and Chu, T. M. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro, 18: 24-34, 1982.
23. Cailleau, R., Young, R., Olive, M., and Reeves, W. J. J. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst., 53: 661-674, 1974.
24. Fogh, J., Wright, W. C., and Loveless, J. D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst., 58: 209-214, 1977.
25. Weiss, A., Wiskocil, R. L., and Stobo, J. D. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J. Immunol., 133: 123-128, 1984.
26. Weiss, A., and Stobo, J. D. Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line. J. Exp. Med., 160: 1284-1299, 1984.
27. Pileri, S. A., Roncador, G., Ceccarelli, C., Piccioli, M., Briskomatis, A., Sabattini, E., Ascani, S., Santini, D., Piccaluga, P. P., Leone, O., Damiani, S., Ercolessi, C., Sandri, F., Pieri, F., Leoncini, L., and Falini, B. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J. Pathol., 123: 116-123, 1997.
28. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., and Sette, A. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity, 1: 751-761, 1994.
29. Wentworth, P. A., Celis, E., Crimi, C., Stitely, S., Hale, L., Tsai, V., Serra, H. M., Del Guercio, M. F., Livingston, B., and Alazard, D. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Mol. Immunol., 32: 603-612, 1995.
30. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
31. Saito, T., Weiss, A., Gunter, K. C., Shevach, E. M., and Germain, R. N. Cell surface T3 expression requires the presence of both α- and β-chains of the T cell receptor. J. Immunol., 139: 625-628, 1987.
32. Saito, T., and Germain, R. N. Predictable acquisition of a new MHC recognition specificity following expression of a transfected T-cell receptor β-chain gene. Nature (Lond.), 329: 256-259, 1987.
33. Staerz, U. D., Rammensee, H. G., Benedetto, J. D., and Bevan, M. J. Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor. J. Immunol., 134: 3994-4000, 1985.
34. Casanova, J. L., Romero, P., Widmann, C., Kourilsky, P., and Maryanski, J. L. T cell receptor genes in a series of class I major histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a Plasmodium berghei nonapeptide: implications for T cell allelic exclusion and antigen-specific repertoire. J. Exp. Med., 174: 1371-1383, 1991.
35. Gillis, S., and Smith, K. A. Long term culture of tumour-specific cytotoxic T cells. Nature (Lond.), 268: 154-156, 1977.
36. Diamond, D. J., York, J., Sun, J. Y., Wright, C. L., and Forman, S. J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood, 90: 1751-1767, 1997.
37. McCarty, T. M., Yu, Z., Liu, X., Diamond, D. J., and Ellenhorn, J. D. An HLA-restricted, p53 specific immune response from HLA transgenic p53 knockout mice. Ann. Surg. Oncol., 5: 93-99, 1998.
38. Peralta, E. A, McCarty, T. M., Doerr, A., Jones, P. A., Markl, I., Diamond, D. J., and Ellenhorn, J. D. Immunotherapy of bladder cancer: targeting p53 in a SCID mouse model. J. Urol., 162: 1806-1811, 1999.
39. Yu, Z., Liu, X., McCarty, T. M., Diamond, D. J., and Ellenhorn, J. D. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J. Surg. Res., 69: 337-343, 1997.
40. Inaba, T., Koseki, H., Suzuki, M., and Taniguchi, M. Double-step and inverse polymerase chain reaction for sensitive detection and cloning of T cell receptor variable region sequences. Int. Immunol., 3: 1053-1057, 1991.
41. Uematsu, Y. A novel and rapid cloning method for the T-cell receptor variable region sequences. Immunogenetics, 34: 174-178, 1991.
42. Saito, T., Weiss, A., Miller, J., Norcross, M. A., and Germain, R. N. Specific antigen-1a activation of transfected human T cells expressing murine Ti αβ-human T3 receptor complexes. Nature (Lond.). 325: 125-130, 1987.
43. Diamond, D. J., Szalay, P., Symer, D., Hao, P., Shin, H. S., Dintzis, R. Z., Dintzis, H. M., Reinherz, E. L., and Siliciano, R. F. Major histocompatibility complex independent T cell receptor-antigen interaction: functional analysis using fluorescein derivatives. J. Exp. Med., 174: 229-241, 1991.
44. Dembic, Z., Haas, W., Weiss, S., McCubrey, J., Kiefer, H., Von Boehmer, H., and Steinmetz, M. Transfer of specificity by murine α and βT-cell receptor genes. Nature (Lond.), 320: 232-238, 1986.
45. Cole, D. J., Weil, D. P., Shilyansky, J., Custer, M., Kawakami, Y., Rosenberg, S. A., and Nishimura, M. I. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res., 55: 748-752, 1995.
46. Clay, T. M., Custer, M. C., Sachs, J., Hwu, P., Rosenberg, S. A., and Nishimura, M. I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol., 163: 507-513, 1999.
47. McCarty, T. M., Yu, Z., Liu, X., Diamond, D. J., and Ellenhorn, J. D. An HLA-restricted, p53 specific immune response from HLA transgenic p53 knockout mice. Ann. Surg. Oncol., 5: 93-99, 1998.
48. Garcia, K. C., Scott, C. A., Brunmark, A., Carbone, F. R., Peterson, P. A., Wilson, I. A., and Teyton, L. CD8 enhances formation of stable T-cell receptor/MHC class 1 molecule complexes. Nature (Lond.), 384: 577-581, 1996.
49. Nunes, J., Klasen, S., Ragueneau, M., Pavon, C., Couez, D., Mawas, C., Bagnasco, M., and Olive, D. CD28 mAbs with distinct binding properties differ in their ability to induce T cell activation: analysis of early and late activation events. Int. Immunol., 5: 311-315, 1993.
50. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991.
51. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
52. Chang, F., Syrjanen, S., and Syrjanen, K. Implications of the p53 tumor-suppressor gene in clinical oncology. J. Clin. Oncol., 13: 1009-1022, 1995.
53. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA, 86: 8763-8767, 1989.
54. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., and Levine, A. J. Activating mutations tor transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol., 8: 531-539, 1988.
55. Reich, N. C., and Levine, A. J. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature (Lond.), 308: 199-201, 1984.
56. Ropke, M., Regner, M., and Claesson, M. H. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol., 42: 98-103, 1995.
57. Houbiers, J. G., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J., Brand, A., Momburg, F., Kast, W. M., and Melief, C. J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23: 2072-2077, 1993.
58. Nijman, H. W., Houbiers, J. G., van der Burg, S. H., Vierboom, M. P., Kenemans, P., Kast, W. M., and Melief, C. J. Characterization of cytotoxic T lymphocyte epitopes of a self- protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother., 14: 121-126, 1993.
59. Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., Van der Burg, S., Nijman, H. W., Melief, C. J., and Claesson, M. H. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA, 93: 14704-14707, 1996.
60. Chikamatsu, K., Nakano, K., Storkus, W. J., Appella, E., Lotze, M. T., Whiteside, T. L., and DeLeo, A.B. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin. Cancer Res., 5: 1281-1288, 1999.
61. Gnjatic, S., Cai, Z., Viguier, M., Chouaib, S., Guillet, J. G., and Choppin, J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J. Immunol., 160: 328-333, 1998.
62. Schmid, P., Lorenz, A., Hameister, H., and Montenarh, M. Expression of p53 during mouse embryogenesis. Development (Camb.), 113: 857-865, 1991.
63. Goverman, J., Gomez, S. M., Segesman, K. D., Hunkapiller, T., Laug, W. E., and Hood, L. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell, 60: 929-939, 1990.
64. Hekele, A., Dall, P., Moritz, D., Wels, W., Groner, B., Herrlich, P., and Ponta, H. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. Int. J. Cancer, 68: 232-238, 1996.
65. Eshhar, Z., Waks, T., Gross, G., and Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA, 90: 720-724, 1993.
66. Norment, A. M., Salter, R. D., Parham, P., Engelhard, V. H., and Littman, D. R. Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature (Lond.), 336: 79-81, 1988.
67. Pierres, A., Lopez, M., Cerdan, C., Nunes, J., Olive, D., and Mawas, C. Triggering CD 28 molecules synergize with CD 2 (T 11.1 and T 11.2)- mediated T cell activation. Eur. J. Immunol., 18: 685-690, 1988.
68. Rooney, C. M., Smith, C. A., Ng, C. Y., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D. K., Bowman, L. C., Krance, R. A., Brenner, M. K., and Heslop, H. E. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92: 1549-1555, 1998.
69. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., and Riddell, S. R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med., 333: 1038-1044, 1995.